Table 3.
Excess mortality rates among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient characteristics, the China National Free Antiretroviral Treatment Program 2003 – 2009†
| Characteristic | 2003–2004 | 2005–2007 | 2008–2009 |
|---|---|---|---|
| Age | |||
| 18–29 | 11.0 (8.0 – 15.1) | 5.9 (5.2 – 6.7) | 3.3 (3.0 – 3.7) |
| 30–44 | 9.2 (8.4 – 10.1) | 6.1 (5.8 – 6.4) | 5.1 (4.9 – 5.3) |
| ≥45 | 8.8 (7.8 – 10.0) | 7.7 (7.3 – 8.1) | 6.5 (6.2 – 6.9) |
| Gender | |||
| Men | 11.3 (10.3 – 12.4) | 7.9 (7.6 – 8.2) | 6.1 (5.9 – 6.3) |
| Women | 7.2 (6.4 – 8.1) | 5.2 (4.9 – 5.5) | 4.1 (3.9 – 4.3) |
| HIV exposure | |||
| Blood transfusion/former plasma donation | 9.1 (8.4 – 9.8) | 6.7 (6.5 – 7.0) | 5.5 (5.3 – 5.8) |
| Intravenous drug use | N/A‡ | 6.0 (5.2 – 6.9) | 7.3 (6.8 – 7.9) |
| Sexual transmission | 8.6 (5.3 – 13.8) | 6.4 (5.9 – 7.0) | 4.0 (3.8 – 4.3) |
| Area of residence | |||
| Rural | 9.1 (8.4 – 9.8) | 6.6 (6.4 – 6.8) | 5.6 (5.4 – 5.8) |
| Urban | 10.9 (7.1 – 16.7) | 6.4 (5.9 – 7.0) | 4.3 (4.0 – 4.6) |
| Health care setting | |||
| General hospital | 19.1 (11.5 – 31.7) | 6.5 (5.9 – 7.2) | 5.2 (4.9 – 5.5) |
| Infectious diseases hospital | 5.0 (2.4 – 10.5) | 4.6 (4.0 – 5.4) | 2.4 (2.1 – 2.7) |
| Centers for diseases control clinic | 13.5 (10.7 – 17.1) | 7.4 (6.8 – 8.1) | 6.1 (5.7 – 6.5) |
| Health care under township level/prison hospital | 8.8 (8.1 – 9.5) | 6.6 (6.3 – 6.9) | 5.7 (5.4 – 6.0) |
| CD4 count (cells/μL) | |||
| 0–49 | 27.8 (23.1 – 33.4) | 15.5 (14.6 – 16.4) | 9.1 (8.6 – 9.6) |
| 50–199 | 7.8 (6.4 – 9.4) | 5.9 (5.5 – 6.3) | 4.9 (4.6 – 5.2) |
| 200–349 | 1.2 (0.7 – 1.9) | 2.5 (2.2 – 2.8) | 2.7 (2.5 – 3.0) |
| ≥350 | 1.9 (1.3 – 2.8) | 1.4 (1.2 – 1.7) | 2.1 (1.8 – 2.5) |
| Number of baseline symptom | |||
| 0 | 8.0 (6.3 – 10.1) | 2.9 (2.6 – 3.3) | 2.6 (2.4 – 2.8) |
| 1 | 5.6 (4.2 – 7.5) | 4.8 (4.3 – 5.4) | 4.5 (4.1 – 5.0) |
| 2–3 | 6.3 (5.4 – 7.4) | 6.4 (6.0 – 6.8) | 5.6 (5.3 – 6.0) |
| ≥4 | 12.1 (11.0 – 13.3) | 8.5 (8.1 – 8.9) | 7.1 (6.8 – 7.4) |
| Initiation regimen* | |||
| NVP+3TC+AZT | 5.2 (2.3 – 11.6) | 5.7 (5.0 – 6.5) | 4.7 (4.4 – 5.1) |
| NVP+3TC+D4T | 0.8 (0.2 – 3.2) | 7.6 (7.2 – 8.1) | 4.9 (4.6 – 5.2) |
| NVP+DDI+AZT | 10.8 (10.0 – 11.7) | 6.8 (6.5 – 7.1) | 6.0 (5.6 – 6.4) |
| NVP+DDI+D4T | 6.5 (5.4 – 7.9) | 4.8 (4.3 – 5.4) | 4.0 (3.4 – 4.7) |
| EFV+3TC+AZT | N/A‡ | 2.9 (2.1 – 4.1) | 4.8 (4.2 – 5.5) |
| EFV+3TC+D4T | N/A‡ | 7.5 (6.2 – 9.0) | 6.7 (6.0 – 7.5) |
| Other regimens | 4.8 (3.0 – 7.6) | 4.8 (3.9 – 5.9) | 7.1 (6.0 – 8.5) |
†
All of excess mortality rates were per 100 person-years
‡
N/A: excess mortality rates were not estimated within strata with fewer than 100 patients.
*
NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz.